[go: up one dir, main page]

BRPI0214840B8 - métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa - Google Patents

métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa

Info

Publication number
BRPI0214840B8
BRPI0214840B8 BRPI0214840A BR0214840A BRPI0214840B8 BR PI0214840 B8 BRPI0214840 B8 BR PI0214840B8 BR PI0214840 A BRPI0214840 A BR PI0214840A BR 0214840 A BR0214840 A BR 0214840A BR PI0214840 B8 BRPI0214840 B8 BR PI0214840B8
Authority
BR
Brazil
Prior art keywords
methods
detecting
mutation
assay
identifying
Prior art date
Application number
BRPI0214840A
Other languages
English (en)
Other versions
BRPI0214840B1 (pt
BR0214840A (pt
Inventor
Futreal Andy
Marshall Chris
Stratton Mike
Malcolm Marais Richard
Wooster Richard
Original Assignee
The Wellcome Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130796A external-priority patent/GB0130796D0/en
Application filed by The Wellcome Trust filed Critical The Wellcome Trust
Publication of BR0214840A publication Critical patent/BR0214840A/pt
Publication of BRPI0214840B1 publication Critical patent/BRPI0214840B1/pt
Publication of BRPI0214840B8 publication Critical patent/BRPI0214840B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"genes". a invenção se refere a mutações nos produtos de gene b-raf. as mutações descritas são identificadas em tumores humanos de origem natural. essas mutações estão associadas com fenótipos cancerosos e podem ser usadas como uma base para o diagnóstico do câncer, células cancerosas ou uma predisposição ao câncer em indivíduos humanos, e ao desenvolvimento de terapêuticos anti-câncer.
BRPI0214840A 2001-12-21 2002-12-23 métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa BRPI0214840B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0130796.6 2001-12-21
GB0130796A GB0130796D0 (en) 2001-12-21 2001-12-21 Genes
US34468401P 2001-12-24 2001-12-24
US60/344,684 2001-12-24
PCT/GB2002/005891 WO2003056036A2 (en) 2001-12-21 2002-12-23 Genes

Publications (3)

Publication Number Publication Date
BR0214840A BR0214840A (pt) 2004-08-31
BRPI0214840B1 BRPI0214840B1 (pt) 2020-12-08
BRPI0214840B8 true BRPI0214840B8 (pt) 2021-05-25

Family

ID=26246901

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0214840A BRPI0214840B8 (pt) 2001-12-21 2002-12-23 métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa

Country Status (8)

Country Link
US (2) US7947819B2 (pt)
EP (1) EP1456364B1 (pt)
JP (2) JP4643909B2 (pt)
AU (1) AU2002353228B2 (pt)
BR (1) BRPI0214840B8 (pt)
CA (1) CA2471114C (pt)
NZ (1) NZ532780A (pt)
WO (1) WO2003056036A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
AU2003286447A1 (en) * 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US20070020657A1 (en) * 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2651995C (en) 2006-05-18 2017-04-25 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
CA2704048A1 (en) * 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
EA019974B1 (ru) 2007-12-19 2014-07-30 Кансер Рисерч Текнолоджи Лимитед 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US8728763B2 (en) 2009-08-11 2014-05-20 Response Genetics Methods, primers, probes and kits useful for the detection of BRAF mutations
US8815896B2 (en) 2010-02-01 2014-08-26 The Institute Of Cancer Research: Royal Cancer Hospital 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
EP4527945A3 (en) 2019-11-06 2025-06-18 The Board of Trustees of the Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981731A (en) * 1994-05-31 1999-11-09 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of B-raf gene expression
US6432634B1 (en) * 1996-04-18 2002-08-13 Visible Genetics Inc. Method, apparatus and kits for sequencing of nucleic acids using multiple dyes
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
DE59802537D1 (de) * 1997-04-15 2002-01-31 Gmd Gmbh Frei programmierbares, universelles parallel-rechnersystem zur durchführung von allgemeinen berechnungen
CA2315717C (en) * 1997-12-22 2011-02-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
GB9919226D0 (en) * 1999-08-13 1999-10-20 Medical Res Council Allele detection

Also Published As

Publication number Publication date
BRPI0214840B1 (pt) 2020-12-08
US20050186584A1 (en) 2005-08-25
US8580497B2 (en) 2013-11-12
AU2002353228B2 (en) 2008-09-11
CA2471114C (en) 2012-03-20
US20110189688A1 (en) 2011-08-04
BR0214840A (pt) 2004-08-31
WO2003056036A3 (en) 2003-12-31
WO2003056036A2 (en) 2003-07-10
JP2010246545A (ja) 2010-11-04
JP2006503542A (ja) 2006-02-02
EP1456364A2 (en) 2004-09-15
CA2471114A1 (en) 2003-07-10
JP4643909B2 (ja) 2011-03-02
NZ532780A (en) 2006-10-27
EP1456364B1 (en) 2011-03-23
US7947819B2 (en) 2011-05-24
AU2002353228A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
BRPI0214840B8 (pt) métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
Lee et al. Forensic DNA methylation profiling from evidence material for investigative leads
Ono et al. Association of dietary and genetic factors related to one‐carbon metabolism with global methylation level of leukocyte DNA
Kim et al. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy
WO2004076643A3 (en) CIRCULATING TUMOR CELLS (CTC’s): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
TW200700558A (en) A method for the detection of chromosomal aneuploidies
Chen et al. Unique and recurrent mutations in the filaggrin gene in Singaporean Chinese patients with ichthyosis vulgaris
WO2005024603A3 (en) Methods for detecting, diagnosing and treating human renal cell carcinoma
Leahy et al. Candidate regions for a testicular cancer susceptibility gene
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
Clarke et al. Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
ATE496635T1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sind
Shimada et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group
ATE197964T1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
Guney et al. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
ATE264922T1 (de) Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe
Rayner et al. Phenotypic and genotypic analysis of amelanotic and hypomelanotic melanoma patients
WO2003025141A3 (en) Genetic analysis for stratification of cancer risk
Zhou et al. The radiosensitivity of human fibroblast cell lines correlates with residual levels of DNA double-strand breaks
Woollard et al. Independent loss of methylthioadenosine phosphorylase (MTAP) in primary cutaneous T-cell lymphoma
Akula et al. Computational analysis of epidermal growth factor receptor mutations predicts differential drug sensitivity profiles toward kinase inhibitors
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
Milingou et al. Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/12 , C07K 16/40 , C12Q 1/48 , C12Q 1/68

Ipc: C12N 9/12 (2006.01), C07K 16/40 (2006.01), C12Q 1/

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2283 DE 07/10/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/12/2022